Monday, January 24, 2022
by Pat Maloney
A report on a Mifegymiso case of a 17 year old with serious, life threatening complications
“Linepharma is a pharmaceutical company committed to improving sexual and reproductive health through expanding access to safe medication abortion.”
Further to my last post about the company whose only product kills babies in the womb, I did an Access To Information request to Health Canada on the abortion drug Mifegymiso. My request:
“I would like to obtain the total number of medical abortions (mifepristone and misoprostol) dispensed in Canada since the drug became legal in 2017. I would also like to see any reports of adverse affects attributed to these medical abortions in Canada since the drug became legal in 2017.”
I am still waiting for the first part of my request, and received information back on the second part about adverse effects.
The first woman I will discuss who suffered from this dangerous drug was 17 years old. There are records for her from 2017, 2018, 2019 and 2020 in the system. I have no idea how long she suffered from her abortion, but there was a lot of paper work done on her.
Her case was classified as serious, life threatening.
This woman suffered the following horrible reactions to this drug:
Loss of consciousness, Hemoglobin low, Iron low, Hemorrhage, Transfusion, Dilation and curettage, Retained products of conception, Heavy bleeding, Large clot, Toxic shock syndrome, Off label use, Escherichia sepsis (E. coli), Septic abortion, Abortion infected, Cardiovascular collapse, Circulatory collapse, Percutaneous cardiopulmonary support, Lung assist device therapy
The case narrative for this young woman: “Septic shock secondary to septic abortion from incomplete medical abortion – was provided mifegymiso at 11-2 GA (well out of recommended gestational age); E.coli identified in blood cultures and from uterine contents; patient presented in cardiovascular collapse to local hospital, was transferred to other hospital level 2 center, urgent D&C carried out and ICU admission required with respiratory/cardiovascular support required, developed septic cardiomyopathy; recovered with extensive antibiotic coverage and intensive care; ultimately was discharged home with close follow-up.”
This case was flagged as off-label use because:
“She had unknown relevant medical history. 11 Weeks 2 days gestation (79 days) patient received Mifegymiso beyond 63 days gestation.” (emphasis added)
Interesting that 63 days number. Because from this Canadian Medical Abortion Dispensing Guide it says up to 70 days. So what is it Linepharma, 63 days or 70 days? And how do you make sure that women don’t take it past this time like this girl did?
On one of the reports was the following comment:
“The case was reported by a physician to Health Canada on 22-Mar-2018 and retrieved by Linepharma on 16-Dec-2019.”
Linepharma took a 21 full months to retrieve the information about this poor girl. You’d think that they would be a tad more interested in knowing about this horror story. And the other horror stories of women taking this dangerous drug that they produce, market, make money from, and send around the world.
How many people in countries not as advanced as Canada suffer from similar reactions? And what will happen if we start sending Mifegymiso to Africa? God only knows.
Action Life notes: Additional information from the Linepharma International product monograph dated April 15, 2019 available on Health Canada’s website :https://pdf.hres.ca/dpd_pm/00050659.PDF
“INDICATIONS AND CLINICAL USE
Mifegymiso (mifepristone tablet/misoprostol tablets) is indicated for medical termination of a
developing intra-uterine pregnancy with a gestational age up to 63 days as measured from the
first day of the Last Menstrual Period (LMP) in a presumed 28-day cycle.”
Health Canada says: “As outlined in the product monograph, Mifegymiso should not be prescribed to patients who are more than nine weeks (63 days) pregnant or have an ectopic pregnancy. ” https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/fact-sheets/mifegymiso.html
Canadian Medical Abortion Dispensing Guide https://www.caps-cpca.ubc.ca/AnnokiUploadAuth.php/8/80/Canadian_Medical_Abortion_Dispensing_Guide_V8_2018-10-18.pdf
“4. Administration of Mifegymiso®
4.1 Indication and clinical use
MIFE200/MISO800 is indicated by Health Canada for pregnancy termination up to 63 days as measured from the first day after the last menstrual period (LMP) in a presumed 28–day cycle. The SOGC indicates safe use up to 70 days LMP. There is no absolute lower gestational age limit and robust clinical data supports the use of MIFE200/MISO800 as an effective regimen up to 70 days.”
N.B.: SOGC stands for Society of Obstetricians and Gynecologists of Canada.